Accessibility Menu
Actuate Therapeutics logo

Actuate Therapeutics(NASDAQ) ACTU

Market Cap$26.56MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2024)-87%
5 YearN/A
1 Year-85%
1 Month-23%
$1.11
-5.13%
-0.06Today
After hours$1.11-$0.00 (-0.45%)
Actuate Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 1.112026-07-31
Actuate Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-5.93%USD 1.182026-07-24
1 month-22.92%USD 1.442026-07-01
3 month-63%USD 3.002026-05-01
Year to date-81.86%USD 6.122025-12-31
1 year-84.69%USD 7.252025-07-31
Since inception-87.11%USD 8.612024-08-13

Actuate Therapeutics Financials at a Glance

Market Cap

$26.56MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$21.54M

EPS (TTM)

-$0.99

P/E Ratio

-1.12

Dividend

$0.00

Beta (Volatility)

1.06 (Average)

Price

$1.11

Volume

157,074.065

Open

$1.19

Previous Close

$1.11

Daily Range

$1.09 - $1.21

52-Week Range

$1.03 - $9.22

Estimated Earnings Date

Aug 13, 2026

ACTU News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Actuate Therapeutics

Actuate develops medicines for people with hard-to-treat cancers. The company focuses on new treatments for cancers.

Lab Bench to Bedside: What Actuate Sells

  • Oral Elraglusib: Tablet version in early testing, designed for easier patient use. (0% of revenue)
  • GSK-3 Inhibitor Portfolio: Collection of experimental cancer drugs licensed from universities. (0% of revenue)

Growth Spurts and Growing Pains

  • Completed Phase 2 trial for Elraglusib in pancreatic cancer with topline data based on a data cutoff of March 27, 2025.
  • Entered equity financing deal with B. Riley Principal Capital II in 2025 for up to $50 million.
  • Raised approximately $4.6 million in a private placement in June 2025.
  • Developing oral Elraglusib with a planned Phase 1 study (timeline not yet announced).

Why Actuate Is a Bit Different

Actuate holds exclusive rights to a group of cancer drug candidates from two major universities. Its main drug targets a protein linked to cancer cell survival and immune response. The company uses both intravenous and oral forms to reach more patients.

Five Things You Need to Know

  • No revenue reported for any period through June 2025.
  • Net loss was $5.9 million in Q2 2025, improving 9.5% from Q2 2024.
  • Cash and cash equivalents were $6.5 million as of June 30, 2025.
  • Operating expenses rose 9.8% year-over-year to $6 million in Q2 2025.
  • Company needs more funding to continue operations beyond October 2025.

Bottom Line

Actuate is a small biotech focused on new cancer treatments, with no sales yet. Its future depends on clinical trial success and securing more funding.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

12

CEO

Daniel M. Schmitt, MBA

Website

www.actuatetherapeutics.com

Headquarters

Fort Worth, TX 76107, US

ACTU Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-430.93%

Return on Capital

-270.08%

Return on Assets

-241.68%

Earnings Yield

-89.29%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$26.56MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

23.93M

Volume

157.07K

Avg. Volume

250.36K

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$21.83M

EBITDA

-$21.52M

Operating Cash Flow

-$19.60M

Capital Expenditure

-$3.00

Free Cash Flow

-$19.60M

Cash & ST Invst.

$8.13M

Total Debt

$404.99K

Actuate Therapeutics Performance Analysis

Actuate Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Actuate Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Actuate Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -1.05N/A
20232023-12-31USD -1.2922.7%
20242024-12-31USD -1.407.9%
20252025-12-31USD -1.06-24.3%
Actuate Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-306.3%
Q32025-09-3016.7%
Q42025-12-3120.0%
Q12026-03-31-20.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$26.56MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$2.21M

N/A

Employees

12

N/A

Net Income

-$5.63M

+10.9%

EBITDA

-$5.62M

+11.0%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$8.13M

+109.1%

Total Debt

$404.99K

N/A

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$404.99K

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-2.42%

N/A

Return on Invested Capital

-5.21%

N/A

Free Cash Flow

-$5.02M

-8.6%

Operating Cash Flow

-$5.02M

-8.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
APLTApplied Therapeutics, Inc.
$0.10+0.00%
VTGNVistaGen Therapeutics, Inc.
$0.24+0.00%
MCRBSeres Therapeutics, Inc.
$4.83+1.05%
ELTXElicio Therapeutics, Inc.
$2.80-3.78%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$200.75+0.03%
AAPLApple
$308.91-0.07%
AMZNAmazon
$271.58+0.15%
INTCIntel
$90.20-0.01%

Questions About ACTU

What is the current price of Actuate Therapeutics?

Actuate Therapeutics is trading at $1.11 per share.

What is the 52-week range for Actuate Therapeutics?

Over the past 52 weeks, Actuate Therapeutics has traded between $1.03 and $9.22.

How much debt does Actuate Therapeutics have?

As of the most recent reporting period, Actuate Therapeutics reported total debt of $404.99K.

How much cash does Actuate Therapeutics have on hand?

Actuate Therapeutics reported $8.13M in cash and cash equivalents in its most recent financial results.

What is Actuate Therapeutics’s dividend yield?

Actuate Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services